Head and neck squamous cell carcinoma (HNSCC) clearly involves activation of the Akt mammalian target of rapamycin (mTOR) signalling pathway. However, the effectiveness of treatment with the mTOR inhibitor rapamycin is often limited by chemoresistance. Melatonin suppresses neoplastic growth via different mechanisms in a variety of tumours. In this study, we aimed to elucidate the effects of melatonin on rapamycin-induced HNSCC cell death and to identify potential cross-talk pathways. We analysed the dose-dependent effects of melatonin in rapamycin-treated HNSCC cell lines (Cal-27 and SCC-9). These cells were treated with 0.1, 0.5 or 1 mmol/L melatonin combined with 20 nM rapamycin. We further examined the potential synergistic effects of melatonin with rapamycin in Cal-27 xenograft mice.
Unexpected Akt activation leads to activation of mTORC1, which contributes to cell growth, proliferation and metabolism, and promotes tumourigenesis. [11] [12] [13] Activation of mTORC1 results in increased protein synthesis and cell survival by direct phosphorylation of its effectors, such as the ribosomal S6K1. It is also well established that S6K1 activation inhibits PI3-kinase signalling, which further attenuate the Akt activation. 14 S6K1 also play a role in mTORC2 activation. 15 Rapamycin is an allosteric inhibitor of mTORC1, which leads to the inhibition of one serine/threonine (Ser/Thr) kinase of the phosphoinositide kinase-related kinase (PIKK) family. 11 The anticancer activity of rapamycin is demonstrated by innumerable scientific and clinical studies, 16, 17 but only in a limited subset of cancer types. Rapamycin analogues, such as temsirolimus and everolimus, are under investigation for HNSCC treatment, but these drugs show poor tolerability and treatment leads to therapy resistance. 18 This counterintuitive observation is largely due to the negative feedback loop from S6K1 to Akt signalling. Rapamycin-induced loss of the feedback inhibition of Akt may actually increase cancer cell survival, potentially resulting in more severe tumours. [18] [19] [20] One means of overcoming this problem may be a combination therapeutic strategy in which the feedback inhibition of Akt is neutralized using other anticancer agents. Melatonin (N-acetyl-5-methoxytryptamine) is a potent free radical scavenger with anti-oxidant and anti-inflammatory properties, [21] [22] [23] [24] [25] [26] [27] [28] which has well-known functions in immune system regulation, 29 modulation of mitochondrial activity, 30 and regulation of cell death 31 and autophagy. 32 Moreover, melatonin has attracted attention as a natural oncostatic agent that can suppress neoplastic growth in a variety of tumours. 33 Melatonin shows synergistic anticancer activity and amelioration of the side effects of several chemotherapies and thus is a potential adjuvant in chemotherapy, 34, 35 with the ability to protect normal cells from a variety of insults. 36, 37 Notably, melatonin also induces downregulation of the phosphorylation of mTOR and Akt in various cancers, including breast cancer 38, 39 and hepatoma cells. 32 In the light of these properties, melatonin seems potentially useful as a combination anticancer agent to enhance the therapeutic effect of rapamycin and to minimize the toxic side effects of this drug in HNSCC. Additionally, mTOR inhibitor treatment is associated with a number of adverse events in cancer patients, 40 with mucositis being the most frequent adverse effect leading to dose reduction or interruption of therapy. 41, 42 We recently demonstrated that a melatonin gel prevents mucosal disruption and ulcer formation associated with oral mucositis. 17, 18 This melatonin pharmaceutical gel is already being tested in phase II clinical trials.
In this study, we investigate the effects of melatonin combined with rapamycin in the HNSCC cell lines Cal-27 and SCC-9. We also tested rapamycin with or without melatonin in tumour-bearing mice, to assess the effectiveness of this combination treatment as a potential antitumour strategy and to evaluate whether melatonin protected against rapamycinmediated toxicity. This study provides the first demonstration of the link between mTOR signalling pathways and mitochondrial function in HNSCC. Our results showed that This led to increase cell death and cellular differentiation. Our data further indicated that melatonin administration reduced rapamycin-associated toxicity to healthy cells.
Overall, our findings suggested that melatonin could be used as an adjuvant agent with rapamycin, improving effectiveness while minimizing its side effects.
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apoptosis, head and neck cancer cells, melatonin, mitochondria, mitophagy, mTOR, rapamycin melatonin induced mTORC1/S6K1 inhibition and enhanced rapamycin-induced cytotoxicity in HNSCC, thus enhancing ROS generation feedback on mitochondria, which could lead to apoptosis or even mitophagy. Overall, our present results indicate that the combination of melatonin with rapamycin may help overcome the limitations of treatment with rapamycin alone.
| MATERIALS AND METHODS

| Chemicals, cell culture and treatment
Human squamous cell carcinoma lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cal 27 cells were maintained in Dulbecco's modified Eagle's medium (DMEM), High Glucose, GlutaMAX supplemented with 10% foetal bovine serum (FBS) and 2% antibiotic/antimycotic solution. SCC-9 cells were grown in a 1:1 mixture of Ham's F-12 and DMEM containing 0.5 mmol/L sodium pyruvate, 0.4 μg/mL hydrocortisone (Sigma-Aldrich, Madrid, Spain), 10% FBS, 1% L-glutamine and 2% antibiotic/antimycotic solution. All cell culture reagents were purchased from Gibco ® -Invitrogen (Thermo Fisher Scientific, Waltham, MA, USA) unless otherwise indicated. The cultures were maintained at 37°C in a humidified atmosphere of 5% CO 2 and 95% air. Melatonin (Fagron Ibérica S.A.U., Terrasa, Spain) stock solution was prepared in 15% propylene glycol (PG) and filter-sterilized through a 0.2-μm-pore filter (Sartorius Biotech GmbH, Gottingen, Germany). Prior to an experiment, melatonin was diluted to the desired concentration directly in the culture medium. Rapamycin (Alfa Aesar, Ward Hill, MA, USA) was dissolved in ethanol and stored at −20°C. Before use, rapamycin solution was freshly prepared by diluting the rapamycin stock in an aqueous solution of 5% Tween 80 and 5% polyethylene glycol. 43 Cells were grown to 60%-70% confluence, serum starved for 24 hours and treated with or without melatonin (0.1, 0.5 or 1 mmol/L) every 48 hours. At 1 hour after the second melatonin treatment, cells were treated with or without rapamycin (20 nmol/L). 44 After another 48 hours, the cells were harvested for further analysis.
| Animals
All experiments were performed following a protocol approved by the Institutional Animal Care and Use Committee of the University of Granada (procedures 11-CEEA-OH-2013), developed in accordance with the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes (CETS # 123) and Spanish law (R.D. 53/2013). This study was conducted using 5-to 6-week-old athymic (nu/nu) nude Harlan Sprague-Dawley mice that were housed in appropriate sterile filter-capped cages, and fed and given water ad libitum. The HNSCC cell line Cal 27 was cultured to subconfluence, trypsinized, washed in PBS and resuspended at a concentration of 4 × 10 6 /0.2 mL in DMEM. Cell viability was assessed using the trypan blue exclusion test, and then 0.2 mL of the cell suspension was subcutaneously (s.c.) transplanted into the left flanks of the mice. 45 Twice weekly, the animals were monitored for tumour development. Once tumour volume reached 100-200 mm 3 , drug treatment was initiated. Rapamycin
(1 mg/kg) was intraperitoneally (i.p.) injected every 2 days for 10 days. 43 To investigate the influence of melatonin, some mice also received s.c. injection of melatonin (300 mg/ kg) 1 day before each rapamycin administration. We used a high dose of melatonin to reach the mitochondria of cancer cells. 46 Melatonin was dissolved in PG and then diluted 1:2 in saline. Rapamycin was dissolved in DMSO and then diluted in an aqueous solution of 40% PEG, 20% PG and 5% Tween 80 in PBS. 43 Mouse body weights were measured using a digital balance, and tumour sizes were determined using a vernier caliper. Tumour volume was calculated as (width × length 2 )/2. 
| Cell morphology, viability and colony formation assay
Cell morphology was observed under an inverted phasecontrast microscope, and pictures were acquired using a camera (OlympusBX61, Tokyo, Japan). Trypan blue staining was performed to assess cell viability. Cells were trypsinized, resuspended in complete medium and then mixed with 0.4% 2× trypan blue buffer. We then added 2 μL of the cell mixture into the haemocytometer and observed the cells under a microscope (Nikon Eclipse Ti, Tokyo, Japan). Blue-stained cells were counted as dead cells. 48 For the colony formation assay, cells from a stock culture were plated following appropriate dilutions (800 and 1000 cells/well for Cal-27 and SCC-9, respectively) into 6-well plates and allowed to attach overnight. Cells were treated with melatonin alone at different concentrations. After 48 hours, the medium was changed and then treated again with melatonin and rapamycin. Colonies were allowed to grow for 2 weeks to form colonies of at least 50 cells each one, following the melatonin treatment every 48 hours. Finally, the colonies were fixed with absolute ethanol and stained with crystal violet. Counting of clones was performed with Image J software after taking the images. 55 The mtDNA values were normalized to nDNA values (mtDNA/nDNA ratio).
| Mitochondrial respiration
To measure the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR), we used an XF24 Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, MA, USA) as previously described. 56 Cells were seeded in XF 24-well cell culture microplates (Seahorse Bioscience) at 8 × 10 4 cells/well and incubated for 24 hours at 37°C under a 5% CO 2 atmosphere. Subsequently, the assays were initiated by replacing the media with assay medium (Seahorse Bioscience). The microplate was then placed into the XF24 instrument to measure the OCR and free protons in the medium. Under typical in vitro cell culture conditions, the OCR is an indicator of mitochondrial respiration. 57 The order and final concentrations of injected substances were 1 μmol/L oligomycin, 1 μmol/L FCCP, 1 μmol/L rotenone and 1 μmol/L antimycin. We recorded an average of 4 readings for each cell line, which was normalized according to the number of cells.
| Western blot analysis
Adequate amounts of proteins were separated on 12.5% or 7% PhastGel homogeneous gels (GE Healthcare Life Sciences, Barcelona, Spain) and then transferred onto Hybond™-ECL™ nitrocellulose membranes (GE Healthcare Life Sciences) using the PhastSystem (GE Healthcare Life Sciences). Next, the membranes were incubated in blocking buffer (5% BSA in PBS plus 0.1% Tween 20), followed by incubation with the primary antibody diluted in blocking buffer overnight at 4°C. 
| Histology and histopathology
For histological analyses, animals were subjected to intracardiac perfusion with 3.7%-4% neutral buffered formaldehyde (fixative). Once perfused, tumours were carefully dissected and immersed in fixative for 48 hours. The fixed samples were dehydrated, cleared and embedded in paraffin following conventional protocols. 58 For morphological evaluation, histological sections of a thickness of 5-μm were dewaxed, hydrated and stained with haematoxylineosin. Staining with picrosirius (PS) was performed to evaluate collagen fibre reorganization, 58, 59 and periodic acid-Schiff histochemical stain (PAS) was used to confirm the mucin synthesis associated with the glandular-like zones of tumours. 
| Melatonin determination by HPLC
We extracted melatonin with trichloromethane and evaporated the organic phase to dryness using a SPD 2010 Speed Vac System (Fisher Scientific, Madrid, Spain). The samples were then analysed by HPLC (Shimadzu Europe GmbH, Duisburg, Germany) using a Waters Sunfire C18 column (150 × 4.5 mm, 5 μm). Melatonin fluorescence was measured using a Shimadzu RF-10A XL fluorescence detector (Shimadzu Europe GmbH) with 285-nm excitation and 345-nm emission wavelengths. 61 
| Statistical analysis
Statistical analyses were performed using GraphPad Prism 6 Scientific software (GraphPad Software, Inc., La Jolla, CA, USA), using one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison post-test. The data were expressed as the mean ± SEM of a minimum of 3 independent experiments. A P value of <.05 was considered to indicate statistical significance.
| RESULTS
| Melatonin inhibits the rapamycininduced feedback activation of Akt in HNSCC
We first investigated how melatonin might influence the effects of rapamycin. To this end, we analysed mTOR pathway activation following melatonin treatment, with or without rapamycin, in the HNSCC cell line Cal-27. The cells were treated for 48 hours with 0, 0.1, 0.5 or 1 mmol/L melatonin and/or 20 nmol/L rapamycin. Then, we performed western blotting to evaluate the downstream target of mTORC1, ribosomal protein S6 (phospho-S6, p-S6). Rapamycin alone significantly decreased S6 phosphorylation in Cal-27 cells, whereas such phosphorylation was not affected by melatonin alone ( Figures 1A,E) . However, p-S6 was significantly reduced in all samples co-treated with rapamycin and any tested concentration of melatonin, indicating that melatonin did not interfere with rapamycin-induced mTOR activation. We next measured Akt expression, which can be elevated via a feedback loop. 62 Rapamycin decreased the level of Akt phosphorylation at the Thr site (p T308 Akt; the mTORC1 phosphorylation site on Akt), in correlation with the reduction of p-S6 ( Figure 1B,E) . On the other hand, rapamycin increased Akt phosphorylation at the Ser site (p S473 Akt; the mTORC2 phosphorylation site on Akt; Figure 1C ,E). These results are consistent with previous findings that rapamycin increases pAkt (S473) levels in several human cancer cell lines. 20, 63 Feedback activation of mTORC1 via phosphorylation of Akt at serine residue 473 by mTORC2 is considered a substantial limitation of mTORC1-specific inhibitors. 62 Therefore, the induction Akt phosphorylation is an unexpected and potentially undesirable consequence of mTOR inhibition. However, treatment with melatonin alone reduced pAkt levels (both S473 and T308), and thereby attenuated the rapamycininduced increase in p S473 Akt ( Figure 1B -E). Consistent with the above results, treatment with a combination of the 2 agents significantly decreased total expression of Akt proteins compared to treatment with rapamycin alone (Figure 1D ,E).
These results indicated that rapamycin inhibited mTOR signalling in vitro and elevated the levels of p S473 Akt. Melatonin did not have effects downstream of p-S6, but alleviated the phosphorylation of Akt, thus inhibiting the feedback loop. These results suggest that the modulation of Akt/ mTOR signalling may be one pathway by which melatonin exerts its effects on HNSCC cancer cells and that melatonin might enhance the oncostatic effects of rapamycin.
| Melatonin enhances effects of rapamycin, sensitizing cells to treatment
We next investigated the combined effects of melatonin and rapamycin on HNSCC cell viability using both Cal-27 and SCC-9 cells. Observation of morphological changes after the treatments revealed that melatonin administration resulted in cell detachment and cell shrinkage (Figure 2A,B) . Surprisingly, trypan blue staining revealed that rapamycin had no significant effects on the viability of either cell line ( Figure 2C,D) . However, melatonin decreased cell viability induced by rapamycin in a dose-dependent manner,
with the maximal effect achieved at a concentration of 1 mmol/L, although the effect is not significantly different from that observed for melatonin alone. Consistent with these results, both Cal-27 and SCC-9 cells lost their clonogenic capacity after treatment with higher concentrations of melatonin ( Figure 2E -G). After 3 weeks, the surviving fraction of rapamycin-treated cells showed only a slight decline compared with controls. However, colony numbers were remarkably lower following melatonin treatment at all concentrations in Cal-27 cells, and particularly with treatment with 1 mmol/L melatonin in SCC-9 cells. The clonogenic assay results confirmed that melatonin caused cell reproductive death. Together, our findings demonstrated that rapamycin had no detectable anticlonogenic capacity in HNSCC Cal-27 and SCC-9 cells. In contrast, the combination of melatonin and rapamycin exerted potent dose-dependent antiproliferative effects in both HNSCC cell lines, although SCC-9 cells were more resistant than Cal-27 cells.
Apoptosis pathway analysis generated similar results. Compared to control, combined treatment with rapamycin and melatonin at concentrations of 0.5 and 1 mmol/L increased expression of the pro-apoptotic protein Bax ( Figure 3A,D) , and decreased expression of the anti-apoptotic protein Bcl2 (Figure 3B,D) , increasing the Bax/Bcl-2 ratio ( Figure 3C ). The Bax/Bcl-2 ratio did not indicate an increase in apoptosis pathway activation upon treatment with rapamycin alone or combined with a low concentration of melatonin (0.1 mmol/L). Thus, only high melatonin concentrations (0.5 and 1 mmol/L) enhanced the cytotoxic effects of rapamycin, leading to apoptosis in HNSCC cell lines.
These results suggested that the tested cell lines showed in vitro resistance to rapamycin. Moreover, combining rapamycin with melatonin significantly decreased cell viability and colony number, and increased apoptosis in a dose-dependent manner. Thus, we demonstrated that rapamycin induced Akt activity and that melatonin inhibited this induction. Notably, mTOR blockade in HNSCC cells reduces the expressions of key molecules involved in cellular metabolism, 64 and mitochondria are the main target of melatonin. 21 Therefore, we further explored the possibility that melatonin could enhance the oncostatic effects of rapamycin via other mechanisms impacting cellular metabolism.
| Melatonin directly controls mitochondrial function, enhancing the biological effects of rapamycin
The ability of melatonin to enhance the cytotoxic effects of rapamycin in HNSCC cells may be related to melatonininduced changes in mitochondrial function. Previous studies show that rapamycin-induced inhibition of mTOR decreases mitochondrial capacity; however, the mechanism by which mTOR is targeted to the mitochondria remains unclear. 65 Thus, we next measured mitochondrial respiration capacity in Cal-27 and SCC-9 cells and found that treatment with rapamycin alone resulted in reduced basal OCR in both Cal-27 and SCC-9 cells ( Figure 4A ,G). We further conducted experiments to assess functionality of the electron transport chain in the presence of rapamycin.
While measuring oxygen consumption rates, we sequentially added oligomycin, carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), and a combination of rotenone and antimycin to the cells to assess the electron transport chain integrity ( Figure 4A,G) . Upon addition of the ATP synthase inhibitor oligomycin, both cell lines showed decreased oxygen consumption while maintaining detectable respiration. This suggested the occurrence of ATP synthesis in conjunction with oxygen consumption and that rapamycin did not uncouple energy production from the electron transport. The cells were then treated with FCCP to uncouple respiration, followed by treatment with a combination of rotenone and antimycin to inhibit complex I and III activity, respectively. As expected, FCCP addition resulted in elevated oxygen consumption to above basal levels, that is, to maximal respiratory capacity (ETS). Addition of rotenone and antimycin completely inhibited mitochondrial respiration ( Figure 4A,G) .
Our data showed that rapamycin decreased basal respiration ( Figure 4C,I ), the ETC ( Figure 4D,J) , ATP turnover ( Figure 4E ,K) and proton leak ( Figure 4F,J) . Together, these findings suggested that rapamycin-treated cells exhibited reduced capacity for oxidative phosphorylation, despite possessing an intact and functional mitochondrial electron transport chain. Moreover, rapamycin decreased ECAR compared to the basal control ( Figure 4B,H) . These results clearly showed that rapamycin could decrease metabolic rate in HNSCC. Importantly, combined treatment with both rapamycin and melatonin induced a sustained reduction in oxygen consumption (Figure 4) , and a marked decrease in proton leak ( Figure 4F,L) . Melatonin also dosedependently increased the ECAR values ( Figure 4B,H) . Both cell lines showed greater proton leak with the combination of melatonin and rapamycin vs rapamycin alone. Interestingly, compared to in SCC-9 cells, Cal-27 cells showed a greater difference in proton leak between the groups treated with and without melatonin ( Figure 4F,L) . These results were consistent with the greater resistance of SCC-9 to the combined treatment in terms of clonogenic capacity. As rapamycin-induced mTOR inhibition decreased oxygen consumption and mitochondrial capacity in both Cal-27 and SCC-9 cells, and the results were more significant in Cal-27 cells, we used this cell line in subsequent experiments.
The results regarding respiration were in line with the observation that melatonin enhances the effects of rapamycin, in terms of decreasing the number of mitochondria or the number of functional mitochondria. To confirm this hypothesis, we next examined OXPHOS, mitochondrial mass and mtDNA. Analysis of OXPHOS by western blot revealed that treatment with melatonin alone led to significant rises in the expressions of respiratory complexes I, III and IV ( Figure 5A,B) . In contrast, treatment with rapamycin alone did not significantly alter the mitochondrial complexes. However, combined treatment increased the levels of complexes I and III compared to the control or treatment with rapamycin alone (Figure 5A,B) , with the greatest effects observed at the highest melatonin concentrations (0.5 and 1 mmol/L).
To examine mitochondrial mass, we used acridine orange. Fluorescence data revealed that the combination of rapamycin and melatonin significantly increased mitochondrial mass compared to treatment with only rapamycin ( Figure 5C ). We also evaluated the synergism between melatonin and rapamycin by analysing mtDNA. The mtDNA/nDNA ratio indicated that combined treatment with rapamycin and 1 mmol/L melatonin significantly increased mtDNA ( Figure 5D ). Overall, our results suggested that melatonin enhanced the cytotoxic effects of rapamycin by augmenting the number of dysfunctional mitochondria.
| Melatonin affects redox homoeostasis in head and neck cancer cells
As melatonin reportedly produces intracellular ROS in tumour cells, 66, 67 we next analysed the redox homoeostasis in the HNSCC cell line Cal-27. Mitochondria-or, more accurately, complex I and complex III of the ETC.-are major sites of ROS production, and our results demonstrated that combined treatment with melatonin plus rapamycin significantly increased the expressions of complex I and complex III. As expected, combined treatment with rapamycin and melatonin significantly and dose-dependently elevated ROS generation compared with rapamycin alone. However, the enhancement of ROS generation by the melatonin/rapamycin combination was abrogated by the use of 1 mmol/L melatonin ( Figure 6A ). Importantly, these results were consistent with analyses of LPO levels ( Figure 6B ) and GSSG/GSH ratio ( Figure 6C ), which also showed that oxidative stress was increased by treatment with rapamycin along with 0.1 or 0.5 mmol/L melatonin, but decreased when using 1 mmol/L melatonin. In agreement with these results, melatonin also dose-dependently suppressed the activity of anti-oxidant enzyme activity, such as GPx, with the most significant effect at 1 mmol/L. These experimental findings supported the possibility that melatonin enhances the effects of rapamycin via inhibition of AKT pathways, and induction of oxidative stress. However, treatment with 1 mmol/L melatonin increased apoptosis and induced the loss of mitochondrial function. To more clearly define the involvement of mitochondrial injury in melatonin/rapamycin-induced cell death, we next analysed mitophagy.
| Melatonin induces mitophagy
Mitophagy can facilitate the death of tumour cells due to excessive removal of mitochondria. 68 We hypothesized that melatonin may induce apoptosis as well as autophagy in HNSCC. 68 To test this hypothesis, we determined the levels of the mitophagy-related proteins LC3-II and Nix ( Figure 7 ). Sequestosome 1 (SQSTM1, p62) is an ubiquitin-binding protein that interacts with the autophagosomal membrane protein LC3 during mitophagy. Lysosomal degradation of autophagosomes leads to a drop in p62 levels. After treatment with higher concentrations of melatonin, we observed a Figure 7C,D) . Together, these data indicated that combined treatment resulted in mitophagy, especially with a 1 mmol/L concentration of melatonin.
| Effect of combined treatment with melatonin and rapamycin in head and neck squamous cell carcinoma xenografts
Based on the effects of combined rapamycin and melatonin treatment in vitro, we investigated whether this combination therapy was more effective at inhibiting tumour growth compared to rapamycin treatment alone. For this purpose, athymic nude mice were injected with Cal-27 cells. Tumourbearing mice were randomly divided into 3 groups: untreated control group (injections of solvent alone), rapamycin treatment and treatment with both rapamycin and melatonin (300 mg/kg). Both rapamycin treatment alone and combined treatment with melatonin and rapamycin resulted in similar significant reductions of tumour volume compared to control mice ( Figure 8A,B) . This was in contrast to the expectation that the combined treatment would be more therapeutically effective than treatment with rapamycin alone, based on our above-described in vitro results. Thus, our in vivo results suggested that melatonin was not reaching the mitochondria at a sufficient concentration, even though the tumours showed a melatonin concentration of 87 ng/mg protein ( Figure 8C ). To further investigate the apparent discrepancy between melatonin's enhancement of rapamycin's effect in vitro and the effects of the combined treatment in head and neck squamous cell carcinoma xenografts, we performed morphological evaluation with standard H&E staining and immunostaining. H&E staining revealed a high number of cells in mitosis in the controls (Figure 9A ), while both treated groups had tumour cells that exhibited signs of apoptosis, characterized by cellular volume reduction (pyknosis), nuclear fragmentation (apoptotic bodies) and chromatin condensation ( Figure 9B,C) . However, the group treated with both melatonin and rapamycin exhibited significantly greater accumulation of apoptotic bodies and more tumour cell necrosis ( Figure 9C) .
In all conditions, histological evaluation revealed a squamous cell carcinoma component mixed with a variable amount of PAS-positive pseudoglandular component, compatible with an adenosquamous carcinoma ( Figure 9D-L) . The 3 treatment conditions showed differences related to tumour differentiation, degree of inflammation and encapsulation. The control was characterized by large and complex cystic cavities surrounded by solid and highly cellular tumour walls. Control tumour cells showed moderate-towell-differentiated squamous zones with horn pearl formation, and irregular pseudoglandular structures containing mucin (PAS-positive reaction; Figure 9D-F) . Additionally, the tumour interior exhibited tumour necrosis, which was surrounded by a discontinued collagen-based capsule ( Figure 9D-F) .
In the group treated with rapamycin alone, histological examination revealed large cystic areas, a well-differentiated squamous component, and PASpositive areas consisting of pseudoglandular structures. Surrounding the tumour mass, we observed a delicate capsule and variable amounts of infiltrating lymphocytes ( Figure 9G-I) . Finally, in the group treated with rapamycin plus melatonin, histological examination revealed a well-differentiated squamous cell carcinoma with a pseudoglandular component (PAS positive; Figure 9J -L). The cystic cavity was reduced relative to the other groups. Curiously, the tumour was mainly surrounded by a collagen-rich capsule ( Figure 9J,K) . Table 1 summarizes additional information related to other histopathological findings.
| Melatonin prevents oxidative stress against rapamycin-induced toxicity in noncancer tissues, lungs, kidneys and liver
Melatonin reportedly protects various organs from chemotherapy-and radiotherapy-induced toxicity. 26, 28, [69] [70] [71] Thus, the combination of melatonin with rapamycin may both achieve an enhanced oncostatic effect and overcome a major limitation of anticancer treatment. Supporting this possibility, we found that melatonin decreased rapamycin-induced LPO in the liver, kidneys and lungs ( Figure 10 ). This indicated that melatonin treatment induced significant protection against rapamycin toxicity in normal cells.
| DISCUSSION
The results of our present study demonstrated a synergistic effect of melatonin and rapamycin with regard to anticancer activity against HNSCC cells. Rapamycin increased p S473 Akt levels, while melatonin abrogated this induction, thus enhancing rapamycin's antitumour effects. Moreover, Rapamycin is an inhibitor of the mTOR pathway and shows a strong anticancer phenotype in both preclinical and clinical trials. However, many cancer types are not sensitive to rapamycin, partially because rapamycin can elevate Akt activity through a feedback loop. 20 Akt can phosphorylate and negatively regulate some substrates such as FOXO transcription factors, GSK3β, Bad, which can block several apoptotic processes. 72 Akt is located at a bifurcation point where differential phosphorylation of distinct residues may lead to activation of mTOR-dependent pathways and/or to the inhibition of apoptotic processes. Therefore, rapamycin-induced Akt activation in tumour cells is likely to reduce its antitumour actions by activating pathways that attenuate its effects on proliferation and apoptosis. In our present study, rapamycin effectively inhibited mTORC1, but also prompted the phosphorylation of Akt (p S473 Akt) in HNSCC. Rapamycin is an allosteric inhibitor of mTORC1, without a direct inhibitory mTORC2 effect. 73 This selective effect on mTOR inhibition is likely to limit the effectiveness of rapamycin on several cancer lines. In the field of cancer research, there is much interest in the use of multiple targeting or dual-targeting agents against mTORC1 and mTORC2 to overcome feedback activation and resistance. 6 However, increased toxicity renders many treatments and drug combinations intolerable, limiting the usefulness of many such approaches. Importantly, our present results showed that melatonin neutralized the rapamycin-induced increase in phosphorylated Akt. Notably, this effect was only observed with a high concentration of melatonin, while low-dose treatment did not seem to impact Akt phosphorylation. Reinforcing our findings, other authors report that pharmacological concentrations of melatonin can lead to inhibition of PI3K/ AKT phosphorylation in breast and ovarian carcinoma. 74, 75 AKT substrates specificity is likely dependent on the ratio between the phosphorylation status of Ser473 and Thr308. 76 Selective phosphorylation of the Ser473 residue is thought to provide protection from stress/drug-induced apoptosis, while melatonin specifically downregulates Ser473 phosphorylation in breast cancer cells. 77 Moreover, we showed that the combination of melatonin and rapamycin overcame the rapamycin-induced apoptosis in the HNSCC cells lines Cal-27 and SCC-9, although rapamycin alone did not increase apoptosis pathway activation. This was observed in association with an upregulation of pro-apoptotic proteins, such as Bax, and downregulation of the anti-apoptotic protein Bcl-2. It has been previously described that melatonin can enhance cytotoxic and pro-apoptotic actions of various chemotherapeutic agents through the participation of melatonin receptors. 78, 79 However, in the present study, the Bax/Bcl2 ratio was strongly regulated by high-dose compared with low-dose melatonin treatment. Melatonin-induced apoptosis in cancer cells is associated with ROS production, [80] [81] [82] and ROS seems to be involved in pathways critically associated with life-span and cell cycle, including the mTOR pathway. 83 As the mitochondrial electron transport chain and OXPHOS are the main sources of cellular ROS, we next addressed the possibility that melatonin acted directly in cancer cell mitochondria to enhance the cytotoxic effects of rapamycin. Our results indicated that the combination of melatonin and rapamycin affected mitochondrial homoeostasis in the HNSCC cells lines. Melatonin decreased mitochondrial respiration capacity, causing a dosedependent increase in ECAR and increasing OXPHOS. These results suggest that even though HNSCC cells lines exhibited depolarized mitochondria and decreased oxygen consumption, they still had active mitochondrial respiration. The cells , liver (C) and heart (D). Treatment groups include control (mice with tumours treated with vehicle), mice treated with rapamycin (Rap) and mice treated with rapamycin plus melatonin at 300 mg/ kg (Rap + aMT). n = 6 per group. Data are presented as mean ± SEM. *P < .05, ***P < .001 vs. control, ###P < .001 vs. rapamycin-treated group possessed functional OXPHOS machinery, but most likely executed respiration decoupled from ATP production. 84 We also found that melatonin increased mitochondrial mass and mtDNA. However, considering that mitochondrial ATP production is positively related to mtDNA copy numbers, 85 our results suggested an increase in nonfunctional mitochondria. We propose that melatonin directly affects the electron transport chain, causing increased ROS production.
Our present results showed a significant and substantial increase in intracellular ROS following combined treatment with melatonin and rapamycin compared to treatment with rapamycin alone. High ROS levels inhibit cell growth and cause apoptosis and necrosis in many tumour cells. 86 Prior studies demonstrate that melatonin increases intracellular ROS in various cancer cells. 87, 88 ROS production was unexpectedly inhibited with melatonin treatment at a concentration of 1 mmol/L. This discrepancy cannot readily be explained, considering that 1 mmol/L melatonin also decreased activity of the anti-oxidant enzyme GPx. We inferred that at high melatonin concentration, ROS accumulation under respiratory conditions may have resulted in mitochondrial protein degradation and even mitophagy. Mitophagy is the main cellular mechanism for removing damaged mitochondrial and proteins. 89 In accordance with this hypothesis, we detected increased expressions of LC3-II and NIX, and degradation of p62 following treatment with high melatonin concentrations. These results indicate that high concentrations of melatonin contribute to initiating mitophagy and eliminating dysfunctional mitochondria. That is likely because ROS accumulation causes severe damage to mitochondrial proteins, triggering mitophagy to limit the mitochondrial damage. The role of mitophagy in cancers is controversial. Mitophagy can facilitate survival by allowing adaptation to stress or can promote cell death due to excessive removal of mitochondria. 90 Sentelle and coworkers 68 showed that mitophagy induction can lead to tumour cell death via an mechanism involving autophagy. Studies also demonstrate that some antitumour drugs activate autophagy while inducing apoptosis. 91, 92 These results are consistent with our present findings showing that 1 mmol/L melatonin enhanced the melatonin-induced apoptosis and mitophagy. Our present study is the first to show a link between melatonin-induced mitophagy and apoptosis in HNSCC, which could lead to the development of new strategies for cancer treatment. We next addressed the possibility that melatonin could enhance rapamycin's cytotoxicity in tumour cells in vivo. Surprisingly, we observed similar growth-inhibitory effects following treatment with rapamycin alone and in combination with melatonin. These results suggested that the melatonin concentration achieved in the tumour was insufficient to enhance rapamycin's cytotoxic effect in vivo. However, histological analysis revealed damaged tumour cells following in vivo treatment with both rapamycin alone and in combination with melatonin, with increased apoptosis and greater cell differentiation in the group that received combined treatment compared to rapamycin alone.
Numerous recent reports show that complexes I and III play pivotal roles in the production of ROS, particularly H 2 O 2 , and could play important roles as cellular messengers and be involved in differentiation and apoptosis. 93 Consistently, our present study revealed that combined treatment with rapamycin and melatonin increased apoptosis and differentiation of tumour cells in vivo. We previously reported that pharmacological doses of melatonin increase neural stem cell differentiation into mature neurons, in a manner that involves an increase in mitochondrial function. 27 The current findings indicate that the observed melatonin-dependent antiproliferative effects require an adequate concentration of melatonin to reach the mitochondria. If melatonin acts in a mitochondriamediated manner, then efficient reduction of tumour growth might require higher melatonin concentrations or an increased treatment duration. Overall, our findings highlight the importance of mitochondrial and cell differentiation therapies when using melatonin against cancer cells.
In conclusion, our present results demonstrated that combined treatment with rapamycin and melatonin enhanced the cytotoxic effects of rapamycin in HNSCC cells. Moreover, we found that this effect involved relationships between mTOR signalling pathways, impaired oxygen consumption, mitochondrial hyperpolarization and oxidative stress. Moreover, our findings suggest that the administration of a high dose of melatonin as an adjuvant in cancer therapy with rapamycin may ameliorate the adverse effects of rapamycin. These observations have important implications for HNSCC treatment, particularly considering the presently low overall 5-year survival (50%), which has not improved much over the past 3 decades.
